Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov) - Dec 14, 2021 - P1/2 | N=86 | Not yet recruiting | Sponsor: German Cancer Research Center | Trial completion date: Jan 2025 ➔ Sep 2025 | Trial primary completion date: May 2023 ➔ Mar 2025
Checkpoint inhibition • First-in-human • Trial completion date • Trial primary completion date • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FOLH1
|